Rosiglitazone Inhibits Adrenocortical Cancer Cell Proliferation by Interfering with the IGF-IR Intracellular Signaling

Rosiglitazone (RGZ), a thiazolidinedione ligand of the peroxisome proliferator-activated receptor (PPAR)-γ, has been recently described as possessing antitumoral properties. We investigated RGZ effect on cell proliferation in two cell line models (SW13 and H295R) of human adrenocortical carcinoma (A...

Full description

Saved in:
Bibliographic Details
Main Authors: Giulia Cantini, Adriana Lombardi, Elisabetta Piscitelli, Giada Poli, Elisabetta Ceni, Sara Marchiani, Tonino Ercolino, Andrea Galli, Mario Serio, Massimo Mannelli, Michaela Luconi
Format: Article
Language:English
Published: Wiley 2008-01-01
Series:PPAR Research
Online Access:http://dx.doi.org/10.1155/2008/904041
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850166985800810496
author Giulia Cantini
Adriana Lombardi
Elisabetta Piscitelli
Giada Poli
Elisabetta Ceni
Sara Marchiani
Tonino Ercolino
Andrea Galli
Mario Serio
Massimo Mannelli
Michaela Luconi
author_facet Giulia Cantini
Adriana Lombardi
Elisabetta Piscitelli
Giada Poli
Elisabetta Ceni
Sara Marchiani
Tonino Ercolino
Andrea Galli
Mario Serio
Massimo Mannelli
Michaela Luconi
author_sort Giulia Cantini
collection DOAJ
description Rosiglitazone (RGZ), a thiazolidinedione ligand of the peroxisome proliferator-activated receptor (PPAR)-γ, has been recently described as possessing antitumoral properties. We investigated RGZ effect on cell proliferation in two cell line models (SW13 and H295R) of human adrenocortical carcinoma (ACC) and its interaction with the signaling pathways of the activated IGF-I receptor (IGF-IR). We demonstrate a high expression of IGF-IR in the two cell lines and in ACC. Cell proliferation is stimulated by IGF-I in a dose- and time-dependent manner and is inhibited by RGZ. The analysis of the main intracellular signaling pathways downstream of the activated IGF-IR, phosphatidyl inositol 3-kinase (PI3K)-Akt, and extracellular signal-regulated kinase (ERK1/2) cascades reveals that RGZ rapidly interferes with the Akt and ERK1/2 phosphorylation/activation which mediates IGF-I stimulated proliferation. In conclusion, our results suggest that RGZ exerts an inhibitory effect on human ACC cell proliferation by interfering with the PI3K/Akt and ERK1/2 signaling pathways downstream of the activated IGF-IR.
format Article
id doaj-art-e516d14082104ec296040230e5f60ed0
institution OA Journals
issn 1687-4757
1687-4765
language English
publishDate 2008-01-01
publisher Wiley
record_format Article
series PPAR Research
spelling doaj-art-e516d14082104ec296040230e5f60ed02025-08-20T02:21:18ZengWileyPPAR Research1687-47571687-47652008-01-01200810.1155/2008/904041904041Rosiglitazone Inhibits Adrenocortical Cancer Cell Proliferation by Interfering with the IGF-IR Intracellular SignalingGiulia Cantini0Adriana Lombardi1Elisabetta Piscitelli2Giada Poli3Elisabetta Ceni4Sara Marchiani5Tonino Ercolino6Andrea Galli7Mario Serio8Massimo Mannelli9Michaela Luconi10DENOthe Center of Excellence for Research, Transfer and High Education: Section of Endocrinology, Department of Clinical Physiopathology, University of Florence, Viale Pieraccini 6, 50139 Firenze, ItalyDENOthe Center of Excellence for Research, Transfer and High Education: Section of Endocrinology, Department of Clinical Physiopathology, University of Florence, Viale Pieraccini 6, 50139 Firenze, ItalyDENOthe Center of Excellence for Research, Transfer and High Education: Section of Endocrinology, Department of Clinical Physiopathology, University of Florence, Viale Pieraccini 6, 50139 Firenze, ItalyDENOthe Center of Excellence for Research, Transfer and High Education: Section of Endocrinology, Department of Clinical Physiopathology, University of Florence, Viale Pieraccini 6, 50139 Firenze, ItalyDENOthe Center of Excellence for Research, Transfer and High Education: Section of Gastroenterology, Department of Clinical Physiopathology, University of Florence, Viale Pieraccini 6, 50139 Firenze, ItalyDENOthe Center of Excellence for Research, Transfer and High Education: Section of Andrology, Department of Clinical Physiopathology, University of Florence, Viale Pieraccini 6, 50139 Firenze, ItalyDENOthe Center of Excellence for Research, Transfer and High Education: Section of Endocrinology, Department of Clinical Physiopathology, University of Florence, Viale Pieraccini 6, 50139 Firenze, ItalyDENOthe Center of Excellence for Research, Transfer and High Education: Section of Gastroenterology, Department of Clinical Physiopathology, University of Florence, Viale Pieraccini 6, 50139 Firenze, ItalyDENOthe Center of Excellence for Research, Transfer and High Education: Section of Endocrinology, Department of Clinical Physiopathology, University of Florence, Viale Pieraccini 6, 50139 Firenze, ItalyDENOthe Center of Excellence for Research, Transfer and High Education: Section of Endocrinology, Department of Clinical Physiopathology, University of Florence, Viale Pieraccini 6, 50139 Firenze, ItalyDENOthe Center of Excellence for Research, Transfer and High Education: Section of Endocrinology, Department of Clinical Physiopathology, University of Florence, Viale Pieraccini 6, 50139 Firenze, ItalyRosiglitazone (RGZ), a thiazolidinedione ligand of the peroxisome proliferator-activated receptor (PPAR)-γ, has been recently described as possessing antitumoral properties. We investigated RGZ effect on cell proliferation in two cell line models (SW13 and H295R) of human adrenocortical carcinoma (ACC) and its interaction with the signaling pathways of the activated IGF-I receptor (IGF-IR). We demonstrate a high expression of IGF-IR in the two cell lines and in ACC. Cell proliferation is stimulated by IGF-I in a dose- and time-dependent manner and is inhibited by RGZ. The analysis of the main intracellular signaling pathways downstream of the activated IGF-IR, phosphatidyl inositol 3-kinase (PI3K)-Akt, and extracellular signal-regulated kinase (ERK1/2) cascades reveals that RGZ rapidly interferes with the Akt and ERK1/2 phosphorylation/activation which mediates IGF-I stimulated proliferation. In conclusion, our results suggest that RGZ exerts an inhibitory effect on human ACC cell proliferation by interfering with the PI3K/Akt and ERK1/2 signaling pathways downstream of the activated IGF-IR.http://dx.doi.org/10.1155/2008/904041
spellingShingle Giulia Cantini
Adriana Lombardi
Elisabetta Piscitelli
Giada Poli
Elisabetta Ceni
Sara Marchiani
Tonino Ercolino
Andrea Galli
Mario Serio
Massimo Mannelli
Michaela Luconi
Rosiglitazone Inhibits Adrenocortical Cancer Cell Proliferation by Interfering with the IGF-IR Intracellular Signaling
PPAR Research
title Rosiglitazone Inhibits Adrenocortical Cancer Cell Proliferation by Interfering with the IGF-IR Intracellular Signaling
title_full Rosiglitazone Inhibits Adrenocortical Cancer Cell Proliferation by Interfering with the IGF-IR Intracellular Signaling
title_fullStr Rosiglitazone Inhibits Adrenocortical Cancer Cell Proliferation by Interfering with the IGF-IR Intracellular Signaling
title_full_unstemmed Rosiglitazone Inhibits Adrenocortical Cancer Cell Proliferation by Interfering with the IGF-IR Intracellular Signaling
title_short Rosiglitazone Inhibits Adrenocortical Cancer Cell Proliferation by Interfering with the IGF-IR Intracellular Signaling
title_sort rosiglitazone inhibits adrenocortical cancer cell proliferation by interfering with the igf ir intracellular signaling
url http://dx.doi.org/10.1155/2008/904041
work_keys_str_mv AT giuliacantini rosiglitazoneinhibitsadrenocorticalcancercellproliferationbyinterferingwiththeigfirintracellularsignaling
AT adrianalombardi rosiglitazoneinhibitsadrenocorticalcancercellproliferationbyinterferingwiththeigfirintracellularsignaling
AT elisabettapiscitelli rosiglitazoneinhibitsadrenocorticalcancercellproliferationbyinterferingwiththeigfirintracellularsignaling
AT giadapoli rosiglitazoneinhibitsadrenocorticalcancercellproliferationbyinterferingwiththeigfirintracellularsignaling
AT elisabettaceni rosiglitazoneinhibitsadrenocorticalcancercellproliferationbyinterferingwiththeigfirintracellularsignaling
AT saramarchiani rosiglitazoneinhibitsadrenocorticalcancercellproliferationbyinterferingwiththeigfirintracellularsignaling
AT toninoercolino rosiglitazoneinhibitsadrenocorticalcancercellproliferationbyinterferingwiththeigfirintracellularsignaling
AT andreagalli rosiglitazoneinhibitsadrenocorticalcancercellproliferationbyinterferingwiththeigfirintracellularsignaling
AT marioserio rosiglitazoneinhibitsadrenocorticalcancercellproliferationbyinterferingwiththeigfirintracellularsignaling
AT massimomannelli rosiglitazoneinhibitsadrenocorticalcancercellproliferationbyinterferingwiththeigfirintracellularsignaling
AT michaelaluconi rosiglitazoneinhibitsadrenocorticalcancercellproliferationbyinterferingwiththeigfirintracellularsignaling